Indivior Plc (INDV) - Financial and Strategic SWOT Analysis Review

  • ID: 4281669
  • SWOT Analysis
  • 59 pages
  • GlobalData
1 of 5

FEATURED COMPANIES

  • AstraZeneca Plc
  • GW Pharmaceuticals Plc
  • Vernalis Plc
  • MORE
Indivior Plc (INDV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities - A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Indivior PLC (Indivior) is a healthcare products provider that develops medicines for opioid addiction treatment. The company offers suboxone used in the treatment of opioid dependence treatment. Its pipeline products include buprenorphine-based products such as RBP-6000 and RBP-6300 for opioid dependence treatment; RBP-8000 for cocaine intoxication; naloxone nasal spray for opiate overdose; arbaclofen placarbil used for alcohol disorders; and RBP-7000 for schizophrenia. Indivior provides analgesic products such as burpex, temgesic and buprenex in different countries. The company offers products in the form of film, tablets, and subutex tabs. It offers its products in the US, Australia, Malaysia, France, Italy, Spain, Germany, Canada and the UK. Indivior is headquartered in Slough, the UK.

Indivior Plc Key Recent Developments

Jul 27,2017: Indivior H1 2017 Financial Results
Feb 22,2017: Indivior: FY 2016 Financial Results
Feb 03,2017: Indivior: Director Declaration
Jan 24,2017: Indivior: Appointment of Non-Executive Director
Nov 02,2016: INDIVIOR: Nine Month Financial Results: Litigation Provision of $220m Booked: Guidance raised.

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AstraZeneca Plc
  • GW Pharmaceuticals Plc
  • Vernalis Plc
  • MORE
Section 1 - About the Company
  • Indivior Plc - Key Facts
  • Indivior Plc - Key Employees
  • Indivior Plc - Key Employee Biographies
  • Indivior Plc - Major Products and Services
  • Indivior Plc - History
  • Indivior Plc - Company Statement
  • Indivior Plc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Indivior Plc - Business Description
  • Indivior Plc - SWOT Analysis
  • SWOT Analysis - Overview
  • Indivior Plc - Strengths
  • Indivior Plc - Weaknesses
  • Indivior Plc - Opportunities
  • Indivior Plc - Threats
  • Indivior Plc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Indivior Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
  • Indivior Plc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
  • Indivior Plc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Jul 27, 2017: Indivior H1 2017 Financial Results
  • Feb 22, 2017: Indivior: FY 2016 Financial Results
  • Feb 03, 2017: Indivior: Director Declaration
  • Jan 24, 2017: Indivior: Appointment of Non-Executive Director
  • Nov 02, 2016: INDIVIOR: Nine Month Financial Results: Litigation Provision of $220m Booked: Guidance raised.
  • Sep 01, 2016: Indivior Appoints Lizabeth Zlatkus As Non-Executive Director
  • Jul 29, 2016: Indivior: H1 2016 Indivior Financial Results
  • Jul 15, 2016: Indivior Announces Intention to List ADRs in U.S.
  • May 20, 2016: Indivior to Present New Data at ISPOR and ICOO that Assess Implications of Adherence, Healthcare Service Utilization and Costs in Opioid Use Disorder
  • May 03, 2016: INDIVIOR Q1 Financial Results Ahead of Plan and Full Year Guidance Confirmed
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About
  • Contact
  • Disclaimer
List of Tables
  • Indivior Plc, Key Facts
  • Indivior Plc, Key Employees
  • Indivior Plc, Key Employee Biographies
  • Indivior Plc, Major Products and Services
  • Indivior Plc, History
  • Indivior Plc, Subsidiaries
  • Indivior Plc, Key Competitors
  • Indivior Plc, Ratios based on current share price
  • Indivior Plc, Annual Ratios
  • Indivior Plc, Annual Ratios (Cont...1)
  • Indivior Plc, Annual Ratios (Cont...2)
  • Indivior Plc, Interim Ratios
  • Indivior Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
  • Indivior Plc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
  • Indivior Plc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Indivior Plc, Performance Chart (2012 - 2016)
  • Indivior Plc, Ratio Charts
  • Indivior Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
  • Indivior Plc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Vernalis Plc
  • Martindale Pharmaceuticals Ltd
  • GW Pharmaceuticals Plc
  • AstraZeneca Plc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll